Please try another search
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Ying Du | 55 | 2014 | Founder, Chairperson & CEO |
Peter Wirth | 71 | 2017 | Independent Director |
Scott W. Morrison | 64 | 2021 | Independent Director |
Leon O. Moulder | 65 | 2020 | Independent Director |
John D. Diekman | 80 | 2017 | Lead Independent Director |
Wing Yu Leung | 53 | 2014 | Independent Director |
Neal Rosen | 73 | 2016 | Member of Scientific Advisory Board |
Kaixian Chen | 77 | 2018 | Independent Director |
Richard B. Gaynor | 73 | 2021 | Independent Director |
Timothy A. Yap | 48 | 2019 | Member of Scientific Advisory Board |
Lieping Chen | 66 | 2019 | Member of Scientific Advisory Board |
Alex A. Adjei | 67 | - | Member of Scientific Advisory Board |
Michel Vounatsos | 61 | 2023 | Independent Director |
Yingyu Liang | 52 | 2014 | Independent Director |
Wing-Yu Leung | 53 | 2014 | Independent Director |
Wing-Yu Leung | 53 | 2014 | Independent Director |
Wing-Yu Leung | 53 | 2014 | Independent Director |
Wing-Yu Leung | 53 | 2014 | Independent Director |
Wing-Yu Leung | 53 | 2014 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review